

# Julia S Johansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4415190/publications.pdf>

Version: 2024-02-01

115  
papers

5,123  
citations

126708

33  
h-index

91712

69  
g-index

117  
all docs

117  
docs citations

117  
times ranked

8502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	13.7	764
2	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. <i>Nature Medicine</i> , 2016, 22, 497-505.	15.2	456
3	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	5.8	393
4	MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 392.	3.8	380
5	Serum YKL-40, A New Prognostic Biomarker in Cancer Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 194-202.	1.1	265
6	Identification of proteins secreted by human osteoblastic cells in culture. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 501-512.	3.1	231
7	Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. <i>European Journal of Clinical Investigation</i> , 1988, 18, 191-195.	1.7	160
8	Plasma YKL-40: a potential new cancer biomarker?. <i>Future Oncology</i> , 2009, 5, 1065-1082.	1.1	137
9	High serum YKL-40 level in patients with small cell lung cancer is related to early death. <i>Lung Cancer</i> , 2004, 46, 333-340.	0.9	116
10	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2887-2894.	0.8	108
11	Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. <i>Oncotarget</i> , 2018, 9, 29820-29841.	0.8	107
12	The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. <i>Clinical Endocrinology</i> , 1991, 35, 471-476.	1.2	101
13	YKL-40 in giant cells and macrophages from patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2624-2630.	6.7	89
14	Increased serum YKL-40 in patients with pulmonary sarcoidosis—a potential marker of disease activity?. <i>Respiratory Medicine</i> , 2005, 99, 396-402.	1.3	86
15	YKL-40 Protein Expression in the Early Developing Human Musculoskeletal System. <i>Journal of Histochemistry and Cytochemistry</i> , 2007, 55, 1213-1228.	1.3	86
16	Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. <i>Journal of Clinical Oncology</i> , 2009, 27, 572-578.	0.8	76
17	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017, 22, 1049-1055.	1.9	73
18	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e99886.	1.1	68

#	ARTICLE	IF	CITATIONS
19	Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2603-2608.	1.1	63
20	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , 2018, 11, 1220-1224.	1.7	63
21	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 75013-75022.	0.8	61
22	Plasma YKL-40 and Total and Disease-Specific Mortality in the General Population. <i>Clinical Chemistry</i> , 2010, 56, 1580-1591.	1.5	57
23	Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	52
24	Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival. <i>Clinical Cancer Research</i> , 2007, 13, 3244-3249.	3.2	51
25	Is YKL-40 a new therapeutic target in cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 219-234.	1.5	48
26	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685.	1.3	48
27	Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. <i>Biomarker Research</i> , 2017, 5, 8.	2.8	48
28	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , 2018, 118, 1609-1616.	2.9	47
29	Serum YKL-40 in Risk Assessment for Colorectal Cancer: A Prospective Study of 4,496 Subjects at Risk of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 621-626.	1.1	45
30	Elevated Plasma YKL-40, Lipids and Lipoproteins, and Ischemic Vascular Disease in the General Population. <i>Stroke</i> , 2015, 46, 329-335.	1.0	45
31	Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality – a cohort study. <i>Journal of Inflammation</i> , 2015, 12, 20.	1.5	42
32	Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. <i>International Journal of Cancer</i> , 2020, 146, 2913-2922.	2.3	41
33	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. <i>PLoS ONE</i> , 2014, 9, e109430.	1.1	39
34	Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. <i>Journal of Rheumatology</i> , 2018, 45, 53-61.	1.0	35
35	The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. <i>International Journal of Cancer</i> , 2016, 139, 2312-2324.	2.3	33
36	Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial. <i>Oncologist</i> , 2022, 27, 67-78.	1.9	30

#	ARTICLE	IF	CITATIONS
37	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 3180-3189.	0.8	29
38	Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 97769-97786.	0.8	28
39	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015, 64, 921-928.	6.1	22
40	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 5655-5667.	3.2	21
41	Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha1 chain (PRO $\alpha$ 1) in patients with pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 149, 228-238.	2.3	21
42	Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. <i>Oncotarget</i> , 2018, 9, 6752-6762.	0.8	21
43	Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. <i>International Journal of Cancer</i> , 2015, 137, 2696-2704.	2.3	20
44	Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. <i>European Journal of Cancer Care</i> , 2020, 29, e13219.	0.7	19
45	Observationally and Genetically High YKL-40 and Risk of Venous Thromboembolism in the General Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1030-1036.	1.1	18
46	Geriatric assessment and intervention in older vulnerable patients undergoing surgery for colorectal cancer: a protocol for a randomised controlled trial (GEPOC trial). <i>BMC Geriatrics</i> , 2021, 21, 88.	1.1	18
47	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. <i>PLoS ONE</i> , 2014, 9, e87746.	1.1	18
48	Genetic variants in <i>CHI3L1</i> influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. <i>Journal of Medical Genetics</i> , 2013, 50, 831-837.	1.5	17
49	Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2650-2659.	0.6	17
50	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 144, 72-80.	1.3	17
51	Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 819.	1.7	17
52	YKL-40 and Alcoholic Liver and Pancreas Damage and Disease in 86258 Individuals from the General Population: Cohort and Mendelian Randomization Studies. <i>Clinical Chemistry</i> , 2014, 60, 1429-1440.	1.5	16
53	Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. <i>Acta Oncologica</i> , 2018, 57, 1445-1454.	0.8	16
54	Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. <i>Scientific Reports</i> , 2021, 11, 865.	1.6	16

#	ARTICLE	IF	CITATIONS
55	Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-year follow-up. <i>International Journal of Cancer</i> , 2020, 146, 2019-2026.	2.3	14
56	Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases. <i>PLoS ONE</i> , 2020, 15, e0236569.	1.1	14
57	Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. <i>Clinical Cancer Research</i> , 2021, 27, 2592-2603.	3.2	14
58	Antibody Directed against Human YKL-40 Increases Tumor Volume in a Human Melanoma Xenograft Model in Scid Mice. <i>PLoS ONE</i> , 2014, 9, e95822.	1.1	14
59	YKL-40 and genetic status of <i>CHI3L1</i> in a large group of asthmatics. <i>European Clinical Respiratory Journal</i> , 2015, 2, 25117.	0.7	13
60	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , 2017, 81, 26-35.	1.3	13
61	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 176-184.	1.1	12
62	Bone Metabolism and Bone Status in Osteoporotic Patients. <i>Acta Medica Scandinavica</i> , 1987, 222, 453-458.	0.0	11
63	Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4144.	1.8	11
64	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881120.	0.8	10
65	Serum YKL-40 and gestational diabetes – an observational cohort study. <i>Apmis</i> , 2016, 124, 770-775.	0.9	8
66	Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 860-865.	0.6	8
67	Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S31330.	3.6	7
68	Circulating tumor necrosis factor- $\alpha$ and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2476-2478.	0.6	7
69	Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. <i>Journal of Hepatology</i> , 2022, 77, 1047-1058.	1.8	7
70	Prognostic evaluation of a new class of liquid biopsy biomarkers in patients with metastatic colorectal cancer: Using the tumor microenvironment as a source of protein biomarkers. <i>Journal of Clinical Oncology</i> , 2018, 36, 3588-3588.	0.8	6
71	Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	6
72	Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4599.	1.7	5

#	ARTICLE	IF	CITATIONS
73	The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. <i>Cardiovascular Endocrinology</i> , 2016, 5, 21-27.	0.8	4
74	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related <i>RAS</i> and <i>BRAF</i> mutation status. <i>International Journal of Cancer</i> , 2021, 148, 2542-2556.	2.3	4
75	Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma – An external validation study. <i>Pancreatology</i> , 2021, 21, 1081-1091.	0.5	4
76	Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. <i>Cancers</i> , 2022, 14, 3250.	1.7	4
77	Plasma YKL-40 in Inuit and Danes. <i>Alcohol and Alcoholism</i> , 2015, 50, 11-17.	0.9	3
78	Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. <i>European Journal of Cancer</i> , 2019, 121, 74-84.	1.3	3
79	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. <i>Scientific Reports</i> , 2021, 11, 7570.	1.6	2
80	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3572-3572.	0.8	2
81	Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4021-4021.	0.8	2
82	Comparative circulating tumor DNA levels for <i>KRAS</i> mutations in patients with nonresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 288-288.	0.8	2
83	MicroRNA biomarkers in whole blood for detection of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4052-4052.	0.8	2
84	Abstract 523: Type XX collagen is elevated in circulation of patients with solid tumors and high levels are associated with higher overall mortality in pancreatic cancer. <i>Cancer Research</i> , 2022, 82, 523-523.	0.4	2
85	Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?. <i>Acta Oncologica</i> , 2019, 58, S42-S48.	0.8	1
86	Genome-wide cfDNA fragmentation in patients with cancer and other diseases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3136-3136.	0.8	1
87	The prognostic value of seven soluble proteins measured in plasma or serum from patients with colorectal cancer in TNM stages I-III.. <i>Journal of Clinical Oncology</i> , 2012, 30, 35-35.	0.8	1
88	Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	0.8	1
89	The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15131-e15131.	0.8	1
90	Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 164-164.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.. Journal of Clinical Oncology, 2015, 33, 4022-4022.	0.8	1
92	Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.. Journal of Clinical Oncology, 2018, 36, e16249-e16249.	0.8	1
93	Genome-wide cell-free DNA fragmentation profiling for early cancer detection.. Journal of Clinical Oncology, 2019, 37, 3018-3018.	0.8	1
94	Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).. Journal of Clinical Oncology, 2022, 40, 554-554.	0.8	1
95	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer, 2021, 158, 248-250.	1.3	0
96	Diagnostic microRNA serum profile in pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 160-160.	0.8	0
97	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548.	0.8	0
98	Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.. Journal of Clinical Oncology, 2012, 30, 8545-8545.	0.8	0
99	The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 1176-1176.	0.6	0
100	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. Journal of Clinical Oncology, 2015, 33, 3548-3548.	0.8	0
101	Prognostic impact of plasma CA 19-9, IL-6 and YKL-40 in patients with inoperable cholangiocarcinoma.. Journal of Clinical Oncology, 2016, 34, e15638-e15638.	0.8	0
102	Prediction of unresectability and overall survival in patients with pancreatic cancer using preoperative plasma CA 19.9, IL-6 and YKL-40.. Journal of Clinical Oncology, 2016, 34, e15689-e15689.	0.8	0
103	The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15060-e15060.	0.8	0
104	The prognostic value of serum IL-6 and YKL-40 in colorectal cancer patients before liver resection.. Journal of Clinical Oncology, 2017, 35, e15078-e15078.	0.8	0
105	Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 267-267.	0.8	0
106	Prognostic biomarker potential of quantifying endotrophin in serum from pancreas cancer patients.. Journal of Clinical Oncology, 2020, 38, e16804-e16804.	0.8	0
107	Title is missing!. , 2020, 15, e0236569.		0
108	Title is missing!. , 2020, 15, e0236569.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!., 2020, 15, e0236569.		0
110	Title is missing!., 2020, 15, e0236569.		0
111	Title is missing!., 2020, 15, e0236569.		0
112	Title is missing!., 2020, 15, e0236569.		0
113	Title is missing!., 2020, 15, e0236569.		0
114	Title is missing!., 2020, 15, e0236569.		0
115	The potential use of blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer.. Journal of Clinical Oncology, 2022, 40, 4082-4082.	0.8	0